The company has announced the relocation into new corporate headquarters located at Sydmarken 11 in Søborg, and the appointment of a new Chief Financial Officer.
The move will accommodate Zealand’s continued workforce growth, which has been steadily increasing to support the number of clinical development programs as well as the longer-term strategic initiative for introducing commercial support, states the company Operations will be able to expand within 7,100 square meters of newly renovated offices and laboratories, and will provide a more open and collaborative working environment.
“This is an exciting time for Zealand Pharma. Extensive thought and effort went into making the decision to relocate from our offices in Glostrup that has been our home for 20 years. However, with our commercial ambitions, we have realized the need to provide head room for growth in addition to modern facilities that will strengthen productivity, talent attraction, and employee satisfaction,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Moving to the new headquarters is a reflection of the success built during the past two decades, and is a milestone in our journey to become a fully integrated biotech company.”
A new Chief Financial Officer
In addition to the relocation of the headquarter, the company has recently announced the appointment of Matthew Dallas as Senior Vice President and Chief Financial Officer, effective October 7, 2019.
“Matthew has extensive public company experience in biotechnology organizations at both the commercial and pre-commercial stages,” said Emmanuel Dulac. “He joins us at a critical point in the company’s journey as we begin commercialization efforts. I am confident that Matthew is the right leader to help us advance into the next phase of growth.”
“I am thrilled to join Zealand Pharma and contribute to the company’s exciting growth trajectory,” said Matthew Dallas. “I look forward to working with the team to champion Zealand’s strong growth potential, lean biotech mindset, and ambitious strategy.”
Most recently, Dallas served as chief financial officer at Aveo Pharmaceuticals, leading finance for the publicly traded biotechnology company and was additionally responsible for investor relations, facilities and information technology. He was previously CFO at CoLucid Pharmaceuticals, which was acquired by Eli Lilly. His earlier career included positions at Genzyme, NEN Life Science Products, and Kimberly Clark. Mr. Dallas holds a bachelor’s degree in Business Administration from the University of Tennessee.
Dallas will be assisted in the transition by Ivan M. Møller, who has served as Zealand’s interim CFO since April 2019. Møller will resume full focus on his continuing role as Senior Vice President of Technical Development & Operations.